Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis
- PMID: 27534428
- PMCID: PMC5843892
- DOI: 10.1177/1470320316657450
Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis
Abstract
Objective: The accuracy of aldosterone/direct renin concentration ratio (ADRR) as a screening test in patients with primary aldosteronism (PA) varies widely across the studies. Therefore, we conducted a meta-analysis to assess the accuracy of ADRR.
Methods: A literature search was performed in PubMed, Embase, and the Cochrane library published between April 1971-February 2016. Studies focusing on the accuracy of ADRR for PA screening were included. Two authors independently extracted information regarding patient characteristics, antihypertensives status, true positives, true negatives, false positives, and false negatives. The random-effects model was used for statistical analysis. Heterogeneity was explored by subgroup analysis and meta-regression.
Results: Nine studies involving 974 patients were included. The overall sensitivity, specificity, area under the curve, and diagnostic odds ratio of ADRR were 0.89 (95% confidence interval (CI) 0.84-0.93), 0.96 (95% CI 0.95-0.98), 0.985 and 324 respectively, with substantial heterogeneity. Meta-regression showed that antihypertensive status affects the ADRR and may account for the heterogeneity (p=0.03). Subgroup analysis of patients who discontinued the antihypertensives revealed a sensitivity of 0.99 (95% CI, 0.95-1.00) and a specificity of 0.98 (95% CI, 0.96-0.99).
Conclusions: This study demonstrates the efficacy of ADRR as a screening test for PA. However, as antihypertensive drugs can interfere with the interpretation of ADRR, it is recommended to interrupt therapy or at least replace with analogues that do not significantly affect the ADRR value.
Keywords: Primary aldosteronism; aldosterone-to-renin ratio; aldosterone/direct renin concentration; direct renin concentration; screening test.
© The Author(s) 2016.
Conflict of interest statement
Figures




Similar articles
-
Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: a systematic review and meta-analysis.Ann Transl Med. 2022 Jun;10(12):679. doi: 10.21037/atm-22-2272. Ann Transl Med. 2022. PMID: 35845504 Free PMC article.
-
Evaluation of aldosterone to direct renin ratio, low renin and related Phenotypes in Afro-Colombian patients with apparent treatment resistant hypertension.Sci Rep. 2024 Aug 5;14(1):18091. doi: 10.1038/s41598-024-67261-w. Sci Rep. 2024. PMID: 39103362 Free PMC article.
-
Diagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism.Int J Mol Sci. 2024 Aug 2;25(15):8453. doi: 10.3390/ijms25158453. Int J Mol Sci. 2024. PMID: 39126022 Free PMC article.
-
Approach to the Patient on Antihypertensive Therapy: Screen for Primary Aldosteronism.J Clin Endocrinol Metab. 2022 Nov 23;107(11):3175-3181. doi: 10.1210/clinem/dgac460. J Clin Endocrinol Metab. 2022. PMID: 35964152 Review.
-
Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension.J Hum Hypertens. 2006 Jul;20(7):482-9. doi: 10.1038/sj.jhh.1002024. Epub 2006 Apr 13. J Hum Hypertens. 2006. PMID: 16617310 Review.
Cited by
-
Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.Front Endocrinol (Lausanne). 2025 Jan 14;15:1372683. doi: 10.3389/fendo.2024.1372683. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39877848 Free PMC article. Review.
-
Radiation dosimetry of para-chloro-2-[18F]fluoroethyl-etomidate: a PET tracer for adrenocortical imaging.EJNMMI Res. 2024 May 21;14(1):48. doi: 10.1186/s13550-024-01109-2. EJNMMI Res. 2024. PMID: 38771379 Free PMC article.
-
Age-Related Cutoffs of Plasma Aldosterone/Renin Concentration for Primary Aldosteronism Screening.Int J Endocrinol. 2018 Jul 16;2018:8647026. doi: 10.1155/2018/8647026. eCollection 2018. Int J Endocrinol. 2018. PMID: 30123268 Free PMC article.
-
Primary aldosteronism - a multidimensional syndrome.Nat Rev Endocrinol. 2022 Nov;18(11):665-682. doi: 10.1038/s41574-022-00730-2. Epub 2022 Aug 31. Nat Rev Endocrinol. 2022. PMID: 36045149 Review.
-
Aldosterone-Secreting Large Oncocytic Neoplasm of the Adrenal Gland with Borderline Potential.Avicenna J Med. 2022 Sep 15;12(4):182-185. doi: 10.1055/s-0042-1756675. eCollection 2022 Oct. Avicenna J Med. 2022. PMID: 36570428 Free PMC article.
References
-
- Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3–17. - PubMed
-
- Kaplan NM. Primary aldosteronism: An update on screening, diagnosis and treatment. J Hypertens 2008; 26: 1708–1709. - PubMed
-
- Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–1248. - PubMed
-
- Gruson D, Maisin D, Lison P, et al. Two-site automated chemiluminescent assay for measurement of immunoreactive renin. Biomarkers 2011; 16: 605–609. - PubMed
-
- Morganti A and European study group for the validation of DiaSorin LDRA. A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. J Hypertens 2010; 28: 1307–1312. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous